BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22283115)

  • 1. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
    Rombolà F; Caravetta A; Mollo F; Spinoso A; Peluso L; Guarino R
    Acta Medica (Hradec Kralove); 2011; 54(4):177-9. PubMed ID: 22283115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
    Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
    [No Abstract]   [Full Text] [Related]  

  • 3. All that glitters: sorafenib.
    Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
    Intern Med; 2011; 50(7):797. PubMed ID: 21467725
    [No Abstract]   [Full Text] [Related]  

  • 4. [Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
    Shiozawa K; Watanabe M; Hirano N; Wakui N; Kikuchi Y; Hara F; Ishii K; Iida K; Sumino Y
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1713-5. PubMed ID: 21996974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
    Di Lorenzo G; Imbimbo M; Leopardo D; Marciano R; Federico P; Buonerba C; Salvatore B; Marinelli A; Palmieri G
    Int J Immunopathol Pharmacol; 2010; 23(3):951-4. PubMed ID: 20943068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
    Dogan E; Aksoy S; Arslan C; Dede DS; Altundag K
    Med Oncol; 2010 Dec; 27(4):1436-7. PubMed ID: 20012235
    [No Abstract]   [Full Text] [Related]  

  • 7. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
    Kim SO; Han SY; Baek YH; Lee SW; Han JS; Kim BG; Cho JH; Nam KJ
    World J Gastroenterol; 2011 Jan; 17(2):267-70. PubMed ID: 21246003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
    Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
    Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report.
    Shiozawa K; Watanabe M; Takenaka H; Nagai H; Ishii K; Sakai K; Sumino Y
    Hepatogastroenterology; 2010; 57(101):688-90. PubMed ID: 21033210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report.
    Park SG; Chung CH; Park CY
    Tumori; 2011; 97(6):794-9. PubMed ID: 22322848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Greten TF; Manns MP; Malek N
    Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 15. [Sorafenib in the treatment of hepatocellular carcinoma].
    Suchánková G; Spicák J
    Vnitr Lek; 2011 May; 57(5):485-90. PubMed ID: 21695929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive squamous cell carcinoma and sorafenib in a black patient.
    Donaldson MR; Stetson CL; Smith JL
    Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
    [No Abstract]   [Full Text] [Related]  

  • 17. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
    Huang WS; Yang CH
    World J Gastroenterol; 2009 Sep; 15(35):4464-6. PubMed ID: 19764104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
    Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
    [No Abstract]   [Full Text] [Related]  

  • 19. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
    Iavarone M; Cabibbo G; Piscaglia F; Zavaglia C; Grieco A; Villa E; Cammà C; Colombo M;
    Hepatology; 2011 Dec; 54(6):2055-63. PubMed ID: 21898496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of variant angina in a patient under chronic treatment with sorafenib.
    Porto I; Leo A; Miele L; Pompili M; Landolfi R; Crea F
    Nat Rev Clin Oncol; 2010 Aug; 7(8):476-80. PubMed ID: 20479781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.